Document Detail

Timing of ibuprofen use and bone mineral density adaptations to exercise training.
Jump to Full Text
MedLine Citation:
PMID:  20200939     Owner:  NLM     Status:  MEDLINE    
Prostaglandins (PGs) are essential signaling factors in bone mechanotransduction. In animals, inhibition of the enzyme responsible for PG synthesis (cyclooxygenase) by nonsteroidal anti-inflammatory drugs (NSAIDs) blocks the bone-formation response to loading when administered before, but not immediately after, loading. The aim of this proof-of-concept study was to determine whether the timing of NSAID use influences bone mineral density (BMD) adaptations to exercise in humans. Healthy premenopausal women (n = 73) aged 21 to 40 years completed a supervised 9-month weight-bearing exercise training program. They were randomized to take (1) ibuprofen (400 mg) before exercise, placebo after (IBUP/PLAC), (2) placebo before, ibuprofen after (PLAC/IBUP), or (3) placebo before and after (PLAC/PLAC) exercise. Relative changes in hip and lumbar spine BMD from before to after exercise training were assessed using a Hologic Delphi-W dual-energy X-ray absorptiometry (DXA) instrument. Because this was the first study to evaluate whether ibuprofen use affects skeletal adaptations to exercise, only women who were compliant with exercise were included in the primary analyses (IBUP/PLAC, n = 17; PLAC/PLAC, n = 23; and PLAC/IBUP, n = 14). There was a significant effect of drug treatment, adjusted for baseline BMD, on the BMD response to exercise for regions of the hip (total, p < .001; neck, p = .026; trochanter, p = .040; shaft, p = .019) but not the spine (p = .242). The largest increases in BMD occurred in the group that took ibuprofen after exercise. Total-hip BMD changes averaged -0.2% +/- 1.3%, 0.4% +/- 1.8%, and 2.1% +/- 1.7% in the IBUP/PLAC, PLAC/PLAC, and PLAC/IBUP groups, respectively. This preliminary study suggests that taking NSAIDs after exercise enhances the adaptive response of BMD to exercise, whereas taking NSAIDs before may impair the adaptive response.
Wendy M Kohrt; Daniel W Barry; Rachael E Van Pelt; Catherine M Jankowski; Pamela Wolfe; Robert S Schwartz
Related Documents :
9200319 - Effect of acute endurance and strength exercise on circulating calcium-regulating hormo...
19461899 - Bone mineral density and secondary hyperparathyroidism in pulmonary hypertension.
17185839 - The influence of mechanical stimulation on osteocyte apoptosis and bone viability in hu...
18550139 - A guide to central place effects in foraging.
15768099 - The quantitative assessment of photodensity of the third carpal bone in the horse.
18599679 - Bones benefits gained by jump training are preserved after detraining in young and adul...
10814599 - Alveolar-capillary membrane dysfunction in chronic heart failure: pathophysiology and t...
3264019 - Normal spect thallium-201 bull's-eye display: gender differences.
9420719 - The impact of clinical data on interpretation of thallium scintigrams.
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.    
Journal Detail:
Title:  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research     Volume:  25     ISSN:  1523-4681     ISO Abbreviation:  J. Bone Miner. Res.     Publication Date:  2010 Jun 
Date Detail:
Created Date:  2010-06-02     Completed Date:  2010-09-01     Revised Date:  2014-09-09    
Medline Journal Info:
Nlm Unique ID:  8610640     Medline TA:  J Bone Miner Res     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1415-22     Citation Subset:  IM    
Copyright Information:
(c) 2010 American Society for Bone and Mineral Research.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adaptation, Physiological / drug effects*
Anti-Inflammatory Agents, Non-Steroidal / administration & dosage*,  pharmacology*
Body Composition / drug effects
Bone Density / drug effects*
Contraceptive Agents
Drug Administration Schedule
Ibuprofen / administration & dosage*,  pharmacology*
Patient Compliance
Time Factors
Young Adult
Grant Support
M01 RR000051/RR/NCRR NIH HHS; M01 RR000051/RR/NCRR NIH HHS; M01 RR000051-47/RR/NCRR NIH HHS; P30 DK048520/DK/NIDDK NIH HHS; P30 DK048520/DK/NIDDK NIH HHS; P30 DK048520-10/DK/NIDDK NIH HHS; R01 AG018857/AG/NIA NIH HHS; R01 AG018857/AG/NIA NIH HHS; R01 AG018857-01/AG/NIA NIH HHS
Reg. No./Substance:
0/Anti-Inflammatory Agents, Non-Steroidal; 0/Contraceptive Agents; WK2XYI10QM/Ibuprofen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): J Bone Miner Res
Journal ID (publisher-id): jbmr
ISSN: 0884-0431
ISSN: 1523-4681
Publisher: Wiley Subscription Services, Inc., A Wiley Company
Article Information
Download PDF
Copyright © 2010 American Society for Bone and Mineral Research
Received Day: 21 Month: 7 Year: 2009
Revision Received Day: 03 Month: 11 Year: 2009
Accepted Day: 29 Month: 12 Year: 2009
Print publication date: Month: 6 Year: 2010
Electronic publication date: Day: 14 Month: 1 Year: 2010
Volume: 25 Issue: 6
First Page: 1415 Last Page: 1422
ID: 3152206
PubMed Id: 20200939
DOI: 10.1002/jbmr.24

Timing of Ibuprofen Use and Bone Mineral Density Adaptations to Exercise Training
Wendy M Kohrt1
Daniel W Barry2
Rachael E Van Pelt1
Catherine M Jankowski1
Pamela Wolfe3
Robert S Schwartz1
1Department of Medicine, Division of Geriatric Medicine, University of Colorado DenverDenver, CO, USA
2Department of Medicine, Division of General Internal Medicine, University of Colorado DenverDenver, CO, USA
3Department of Preventive Medicine and Biometrics, University of Colorado DenverDenver, CO, USA
Correspondence: Address correspondence to: Wendy M Kohrt, Mail stop B179, 12631 East 17th Avenue, Room 8111, Aurora, CO 80045, USA. E-mail:


Prostaglandin E2 (PGE2) increases in bone in response to mechanical loading and appears to be an essential intermediate in the signaling pathway for bone formation (i.e., mechanotransduction).(6,34,36) The key enzyme involved in the production of PGE2 and other prostaglandins is cyclooxygenase (COX). Inhibition of COX with nonsteroidal anti-inflammatory drugs (NSAIDs) markedly diminishes the bone-formation response to mechanical stress in laboratory animals and cultured osteoblasts.(5,79,20) This effect has been observed in response to both nonselective(5,79) and COX-2 selective inhibitors,(9,20) which is consistent with the observation that mechanotransduction is mediated primarily through the activation of COX-2.(2) Importantly, the timing of NSAID administration appears to be a key determinant of the bone-formation response. Formation is significantly attenuated when NSAIDs are administered before mechanical loading, but not when they are administered after.(7,20)

An important limitation of these studies is that they evaluated the bone-formation response to acute mechanical loading only. Thus it is not clear whether the usual effects of repeated bouts of mechanical loading (i.e., exercise training) to increase bone mineral density (BMD) and strength are impaired by NSAID use. Chronic exposure to NSAIDs has been found to have deleterious effects on bone in rats restricted to usual cage activity,(30,32) although this is not a consistent observation.(12) Because PGE2 plays a role in the activation of both bone formation and resorption, chronic NSAID use could have antiformation and/or antiresorptive actions, and the net effect on BMD could be beneficial, detrimental, or neutral.(28) In this context, it is not surprising that the human cohort studies that have examined the associations of NSAID use with BMD, markers of bone turnover, or fracture risk have yielded mixed results.(3,4,19,23,29,35) Importantly, a consistent finding among studies of animals is that NSAIDs markedly diminish the bone-formation response to mechanical stress when administered before loading.

Because there have been no studies, in animals or humans, of the effects of NSAID use on skeletal adaptations to exercise, this study was considered a preliminary, proof-of-concept investigation. The primary aim was to determine whether ibuprofen, a commonly used nonselective COX inhibitor, attenuates the BMD adaptations to exercise training. A second aim was to determine whether the timing of ibuprofen use (i.e., before versus after exercise) influences the adaptive response. Based on the studies of the timing of NSAID administration on the bone-formation response to a single loading bout in animals,(7,20) we hypothesized that taking ibuprofen before exercise sessions would attenuate the increases in BMD in response to exercise training when compared with taking ibuprofen after exercise sessions or with placebo treatment.

Materials and Methods
Study design and participants

This was a randomized, double-blinded, placebo-controlled study of the effects of ibuprofen use and the timing of use relative to performance of exercise on the BMD response to a 9-month exercise training program. Although conducted as a randomized, controlled trial, this was a proof-of-concept study to determine whether there is translation of the skeletal effects of NSAIDS in rodents(7,20) to human physiology. Volunteers provided written informed consent to participate, and the study was approved by the Colorado Multiple Institutional Review Board.

The participants were healthy, eumenorrheic women aged 21 to 40 years. Eumenorrheic status was defined as having a menstrual cycle length of 25 to 31 days and at least 10 cycles in the preceding year. Women on progestin-only contraceptive therapy were excluded, but other hormonal contraceptive therapy was allowed. Other inclusion criteria were exercising less than 3 days per week at moderate to high intensity; body mass index (BMI) of less than 30 kg/m2; nonsmoker for more than 2 years; not pregnant or lactating; no NSAID intolerance or sensitivity; typical NSAID use less than 3 days per month; no use of drugs that affect bone metabolism; serum thyroid-stimulating hormone concentration of 0.5 to 5.0 µU/mL; hematocrit of 30% or greater; serum creatinine concentration of less than 1.4 mg/dL; no history of ulcers, gastrointestinal bleeding, gastroesophageal reflux disease, thrombocytopenia, or bleeding disorders; and no known liver disease, kidney disease, cardiovascular disease, diabetes, or hypertension. Volunteers who met eligibility criteria and were willing to continue in the study (n = 95) were randomized to three treatment arms before starting the supervised 9-month exercise training program: (1) ibuprofen before exercise, placebo after exercise (IBUP/PLAC, n = 31), (2) placebo before exercise, placebo after exercise (PLAC/PLAC, n = 31), and (3) placebo before exercise, ibuprofen after exercise (PLAC/IBUP, n = 33).

Drug intervention

Participants took two study capsules, one before exercise and one after, on each day of supervised exercise. The capsules were prepared by a local pharmacy (Belmar Pharmacy, Lakewood, CO, USA) and contained either ibuprofen 400 mg or inactive ingredients. All capsules were identical in appearance, with the exception that capsules taken 1 to 2 hours before the exercise sessions were green and those taken immediately after exercise were red. Participants recorded the time that the preexercise capsule was taken when they arrived at the exercise facility. The postexercise pill was taken immediately after completing the exercise session, and the time was recorded. Randomization to the three drug-intervention arms was stratified for use of hormonal contraceptive therapy. The University of Colorado Denver Research Pharmacy managed the randomization process, maintained all drug intervention records, and prepared and dispensed study drug packets.

Exercise training intervention

All women in the study participated in a 9-month weight-bearing exercise training program. The general structure of the exercise training program was similar to programs used in previous studies that resulted in increases in BMD.(16,17) Participants were instructed to attend at least three supervised exercise sessions per week. The exercise program included weight-bearing endurance exercises (e.g., walking, jogging, rope jumping, and stair climbing/descending), weight-supported endurance exercise that generates relatively high muscle forces (e.g., rowing), box jumps (e.g., step up onto a platform and jump off, 2-ft landing), and upper and lower body resistance exercises. The lower body, biceps, and triceps exercises were performed unilaterally. Exercise was prescribed initially at a moderate intensity (60% to 70% of maximal heart rate, three sets of 12 to 15 repetitions at 60% to 70% of 1-repetition maximum) for a total of 30 min/day. The duration and intensity of exercise were increased gradually on an individualized basis, with exercise prescriptions updated weekly. Box-jump height started at 8 inches and was increased by 2 inches as tolerated to a maximum of 16 inches. The goal was to perform a combination of high-intensity endurance (80% to 85% of maximal heart rate), resistance (three sets of 8 to 10 repetitions at 70% to 80% of 1-repetition maximum), and jumping exercises for a total exercise time of approximately 45 min/day over the last 3 months of the program, not including time to warm up and cool down.

BMD and body composition

BMD of the total body, lumbar spine (L2–L4), and proximal femur (total, neck, trochanter, and shaft) was measured by dual-energy x-ray absorptiometry (DXA) on a Hologic Delphi-W instrument (Hologic, Inc., Bedford, MA, USA) at baseline and after 9 months of exercise training. The total-body scan also provided measures of fat mass and fat-free mass. In our laboratory, the coefficients of variation (CVs) for lumbar spine, total-hip, femoral neck, trochanter, and shaft (i.e., subtrochanteric region) BMD are (mean ± SD) 1.2% ± 0.8%, 0.8% ± 0.6%, 1.9% ± 0.9%, 1.5% ± 1.0%, and 1.1% ± 0.6%, respectively. CVs for fat-free mass and fat mass are 1.2% ± 0.8% and 1.8% ± 0.9%, respectively. Calibration procedures included spine phantom scans daily, whole-body phantom scans three times per week, air scans once a week, and tissue bar scans once a month.

Statistical analyses

Because there have been no previous intervention studies of the effects of regular NSAID use on BMD adaptations to exercise, this was a physiologic study of the effects that occur when there is compliance with the exercise program. Therefore, the primary data analysis was per protocol rather than intent to treat. Compliance was defined as attending at least 80% of the prescribed exercise sessions over the 9-month intervention (i.e., at least 2.4 per week).

Homogeneity across groups at baseline was verified by one-way analyses of variance for age, BMI, weight, fat mass, fat-free mass, and BMD. A chi-square test for equal proportions across groups was applied to ethnicity and hormonal contraception use. The baseline data also were examined for differences by hormonal contraception use with two-group t tests, chi-square tests, or exact chi-square tests as appropriate.

The effects of ibuprofen on the BMD responses to exercise training were evaluated by analysis of covariance (ANCOVA), regressing the 9-month change in BMD on baseline BMD and group (IBUP/PLAC, PLAC/IBUP, and PLAC/PLAC). The same method was used to assess the effects of age, change in body weight, and use of hormonal contraception. Although p values were not adjusted for multiple comparisons, we protected the type I error rate by requiring a priori that effects be significant for more than one BMD region and by testing for any differences across groups before testing pair-wise differences. Pair-wise comparisons were considered significant only when both the global F and the pair-wise comparison were significant at an alpha level .05 or less. Data are presented as mean ± SD, unless otherwise specified.


Of the 95 volunteers randomized to the drug treatment arms, 73 completed the 9-month exercise program, and 54 completed at least 80% of the prescribed sessions. The attrition and noncompliance rates were higher than expected, but it is unlikely that this was related to the intervention per se. Rather, because the study was carried out during a time interval when the university was moving to a new campus, these factors were negatively influenced by relocation of the exercise training facility twice during the study (i.e., from the old campus to an interim off-campus facility and then to the new campus).

The treatment groups in the subset of participants who were compliant with the intervention were well matched on baseline characteristics (Table 1). There were no significant differences in baseline characteristics between users and nonusers of hormonal contraception (Table 2).

Exercise intervention

There were no significant differences among the groups in the amount of exercise performed during the intervention. Among those who were compliant, the average exercise frequency was 3.4 ± 0.6, 3.4 ± 0.6, and 3.6 ± 0.6 days per week in the IBUP/PLAC, PLAC/PLAC, and PLAC/IBUP groups, respectively. The average volume of exercise performed by all participants in the second month of the study (after participants had become accustomed to the equipment) and in the eighth month of the study (before final follow-up testing began) is summarized in Table 3. Treadmill walking/running was the most commonly performed endurance exercise.

Across the entire 9-month exercise program, the time interval between the preexercise and postexercise drug doses averaged 2.37 ± 0.44, 2.45 ± 0.46, and 2.55 ± 0.46 hours (p = .55) for the IBUP/PLAC, PLAC/PLAC, and PLAC/IBUP groups, respectively. Because the postexercise capsule was taken immediately on completion of an exercise session, this indicates that the preexercise capsule typically was taken about 1.5 hours before an exercise session. Pill compliance, assessed as the percentage of prescribed doses based on exercise frequency, was 83% ± 20%, 80% ± 24%, and 86% ± 16% in the IBUP/PLAC, PLAC/PLAC, and PLAC/IBUP groups, respectively.

Changes in body composition

There were no significant differences among the groups in the changes in fat mass or fat-free mass in response to exercise training (Fig. 1). The changes in fat mass were –2.2 ± 2.5 kg, −2.0 ± 2.2 kg, and −1.3 ± 1.8 kg in the IBUP/PLAC, PLAC/PLAC, and PLAC/IBUP groups, respectively. The respective changes in fat-free mass were 0.4 ± 1.3 kg, 0.8 ± 1.1 kg, and 0.8 ± 1.1 kg.

Changes in BMD

As hypothesized, among women who were compliant with the exercise intervention, taking ibuprofen before exercise (IBUP/PLAC) impaired the increases in BMD when compared with taking ibuprofen after exercise (PLAC/IBUP), although the effect at the lumbar spine was not statistically significant (Fig. 2, top panel). The differences (mean ± SE, adjusted for baseline BMD) between these two groups in the changes in BMD were 0.013 ± 0.008 g/cm2 for the lumbar spine (p = .100), 0.020 ± 0.005 g/cm2 for the total hip (p = .001), 0.018 ± 0.008 g/cm2 for the femoral neck (p = .020), 0.012 ± 0.006 g/cm2 for the trochanter (p = .030), and 0.024 ± 0.009 g/cm2 for the femoral shaft (p = .007). The inclusion of age, change in body weight, or use of hormonal contraception in the analysis model did not change the results. As would be expected, the magnitude of differences between the groups was diminished by the inclusion of participants who were not compliant with exercise (Fig. 2, bottom panel). However, the pattern of group differences remained.

In contrast to the hypothesis, the group that received only placebo treatment (PLAC/PLAC) did not have the most robust increases in BMD. Increases in BMD in this group tended to be only slightly, but not significantly, larger than in the IBUP/PLAC group in some regions (Fig. 2, top panel). Unexpectedly, the increases in BMD adjusted for baseline BMD were significantly greater in the PLAC/IBUP group than in the PLAC/PLAC group at the femoral neck (difference 0.019 ± 0.007 g/cm2, p = .010), hip (0.018 ± 0.005 g/cm2, p = .001), trochanter (0.013 ± 0.005 g/cm2, p = .020), and femoral shaft (0.019 ± 0.008 g/cm2, p = .020); the difference at the lumbar spine was not statistically significant (0.006 ± 0.007 g/cm2, p = .431).


The aim of this study was to determine whether the regular use of ibuprofen before or after exercise sessions influences the BMD adaptations to exercise training. The scientific basis for the study was the evidence from animal studies that the acute increase in bone formation in response to mechanical loading is markedly inhibited when NSAIDs are administered before, but not after, mechanical loading.(7,9,20) Consistent with this evidence, we found that taking ibuprofen before exercise resulted in the least favorable adaptations in BMD. However, in contrast to our expectation that the PLAC/PLAC and PLAC/IBUP groups would have similar increases in BMD, we found that the largest increases occurred in the group that took ibuprofen immediately after completing the exercise sessions.

Ibuprofen and other nonselective and selective COX inhibitors are thought to influence bone metabolism by blocking the production of PGE2.(28) The actions of PGE2 in bone are complex. The seemingly paradoxical findings that PGE2 can both stimulate and inhibit bone formation and resorption may relate to the distribution of the four prostaglandin receptor subtypes in bone.(21) Because the major effects of PGE2 in bone are to stimulate both formation and resorption, blocking PGE2 production with NSAIDs would be expected to have antiformation and antiresorptive effects.(28) Accordingly, the net effect on BMD could be deleterious or favorable depending both on relative balance between the antiformation and antiresorptive activities and on the state of bone turnover.

Because of the potential antiresorptive actions of COX inhibitors, several animal studies have evaluated whether NSAIDs prevent the bone loss that occurs following ovariectomy as a result of the increase in bone turnover. Indeed, in one of the early studies, 6 weeks of naproxen treatment reduced ovariectomy-related bone loss by approximately 70% in adult rats.(18) However, in a follow-up study, the same investigators found that 12 weeks of naproxen was ineffective in preventing ovariectomy-related bone loss in adult rats.(14) Others have confirmed that NSAIDs are ineffective(13) or only partially effective(10,12) in attenuating ovariectomy-related decreases in bone volume or BMD.

Chronic NSAID use also has been found to cause bone loss in laboratory animals. In ovariectomized adult rats, 24 weeks of indomethacin treatment caused greater decreases in lumbar spine BMD, trabecular bone volume, and trabecular thickness than vehicle treatment.(30) Similarly, treatment of young rats with ibuprofen for 28 days had an independent adverse effect on trabecular bone volume in intact, ovariectomized, ovariectomized estrogen-treated, and ovariectomized tamoxifen-treated animals.(32) Male gonad-intact rats treated with a COX-2 selective inhibitor for 30 days had an increase in bone resorption and a decrease in formation but, paradoxically, BMD was preserved.(31) However, as with the studies of naproxen discussed earlier,(14,18) a longer duration of treatment with a COX-2 selective inhibitor may be necessary to determine the true effects of COX-2 inhibitors on BMD. These studies of laboratory animals highlight the complex and variable effects of NSAIDs on bone metabolism, which may be influenced by the age of the animal, bone turnover state, type and dose of NSAID, and duration of treatment.

In contrast to the variable effects of chronic NSAID treatment on bone metabolism in animals, a consistent finding is that NSAIDs impair the bone-formation response to acute mechanical loading. PGE2 was identified as playing a role in mechanical transduction in bone more than 20 years ago.(33) Key evidence that prostaglandins are essential for bone formation came from in vivo mechanical loading experiments in which the expected osteogenic response to mechanical loading was absent when indomethacin was administered.(27) Subsequent studies revealed that the bone-formation response is mediated by COX-2.(2,9) However, in mice lacking COX-2 (i.e., null mutation), a normal bone-formation response to mechanical stimulation was achieved through a compensatory increase in COX-1.(1) This suggests that nonselective COX inhibitors may suppress bone formation to a greater extent than COX-2 selective inhibitors when used chronically.

The timing of NSAID administration relative to mechanical loading has been found to be an important determinant of the bone-formation response. Chow and colleagues were the first to observe that the increase in bone formation in adult rats was suppressed by indomethacin when it was administered before, but not after, mechanical stimulation.(7) This was confirmed subsequently in a study in which a COX-2 inhibitor, NS-398, was administered to rats before or after in vivo mechanical loading of the tibia.(20) NS-398 administered 3 hours or 30 minutes before mechanical loading significantly dampened the bone-formation response, whereas administration 30 minutes after loading did not.

Although there is consistent evidence from studies of animals that the administration of NSAIDs prior to mechanical loading blocks the bone-formation response, a limitation is that the studies have assessed the response to only a single bout of loading. To our knowledge, this study is the first, in humans or animals, to evaluate whether NSAID use, and specifically the timing of use (i.e., before versus after bone-loading exercise), is an important determinant of the adaptation of BMD to repeated mechanical stimulation (i.e., exercise training). Based on the studies of acute loading in animals,(7,20) we hypothesized that taking ibuprofen before exercise sessions would blunt the adaptation in BMD but that taking ibuprofen after exercise sessions would not. The observation that the least favorable changes in BMD tended to occur in the group that took ibuprofen before each exercise training session was interpreted as being consistent with the evidence that COX inhibition prior to loading blocks bone formation.(7,9,20,27) However, the robust increases in BMD in the group that took ibuprofen after exercise were not anticipated. Rather, it was expected that the increases in BMD would be similar in the PLAC/PLAC and PLAC/IBUP groups.

Potential reasons for the smaller than expected BMD changes in the placebo-only group should be considered. One possibility is that because they did not receive any NSAID treatment, the physical discomforts that sometimes occur with vigorous exercise training may have caused them to reduce their physical activity level outside the exercise program. We think that this was unlikely because all participants were instructed to take acetaminophen if they had a need for analgesic therapy. This recommendation was based on the long-standing belief that, in contrast to NSAIDs, the mechanism by which acetaminophen relieves pain does not involve COX suppression. However, recent evidence suggests that acetaminophen does, indeed, act through COX-related mechanisms.(11,15) To our knowledge, the effect of acetaminophen on the bone-formation response to loading has not been studied. However, if effects are similar to those of NSAIDs, and if the group on placebo-only therapy used more acetaminophen than the groups on ibuprofen, then this may have contributed to the small changes in BMD in the placebo group.

Potential reasons for the larger than expected increases in BMD in the group that took ibuprofen after exercise sessions also should be considered. High-intensity endurance and resistance exercise stimulates increases in serum inflammatory cytokines.(22,25,26) For example, serum interleukin 6, which is a potent stimulator of bone resorption,(24) was increased approximately sevenfold 1 hour after a bout of vigorous resistance exercise.(25) In general, intense exercise generates increases in inflammatory cytokines that peak within a few hours of cessation of exercise.(22) If the exercise performed in the current study generated increases in proresorptive cytokines, it is possible that the benefit on BMD of taking ibuprofen immediately after exercise sessions was via the suppression of inflammatory-mediated bone resorption. Further research will be needed to explore such mechanisms.

The bulk of evidence from studies of animals suggests that NSAIDs do not have favorable effects on bone. Accordingly, it might be predicted that chronic NSAID use would be associated with low BMD values in humans. Associations of NSAID use with BMD, bone turnover markers, and/or fracture risk have been evaluated in the Study of Osteoporotic Fractures,(3) Rancho Bernardo Study,(23) Health ABC Study,(4) and Canadian Multicentre Osteoporosis Study.(29) In all these studies, analysis of covariance was used to adjust for an array of parameters likely to be associated with the outcomes of interest. After such adjustments, there was no evidence that NSAID use influenced bone turnover or nonvertebral fracture risk. However, in all four of the cohort studies, there was some evidence for increased BMD levels in some groups of NSAID users when compared with nonusers. As an example, in the Rancho Bernardo Study of women aged 44 to 98 years,(23) regular use of proprionic acid NSAIDs was associated with increased BMD levels of the hip (2% to 3%) and lumbar spine (∼9%).(23) This type of favorable association of NSAID use with BMD in humans is seemingly in contrast with the unfavorable effects of NSAIDs on bone metabolism in laboratory animals. However, in the Canadian Multicentre Osteoporosis cohort study,(29) favorable effects of COX-2 selective inhibitors on BMD were apparent only in postmenopausal women and primarily in those on estrogen-based hormone therapy. In contrast, men who used COX-2 selective inhibitors had significantly lower BMD levels than men who did not. Such findings support the concept that bone turnover state may be an important determinant of the effects of NSAIDs on bone metabolism. In high-turnover conditions (e.g., postmenopausal women not on hormone therapy), the antiresorptive effects of NSAIDs may predominate and have a beneficial effect on BMD, whereas in low-turnover conditions (e.g., men), the antiformation effects may predominate and have an adverse effect on BMD.

This study had some limitations. Participants were instructed to use acetaminophen for pain relief when needed, but there is emerging evidence that acetaminophen has COX inhibitory effects.(11,15) No data were collected regarding the use of this medication. Additionally, we did not control for changes in physical activity outside the exercise intervention; between-group differences in nonintervention exercise or activity could have confounded the findings of the study. This was a small study of premenopausal women, and the results may not be applicable to other patient groups with different rates of bone turnover. Because this was the first intervention study of the effects of the timing of NSAID use on adaptations of bone to mechanical loading, many questions remain regarding the potential influence of the type of NSAID, dose, and specific timing of use relative to exercise.

In summary, taking 400 mg of ibuprofen immediately after exercise sessions augmented the beneficial adaptations of BMD to 9 months of exercise training when compared with taking ibuprofen before exercise or with placebo therapy. Because of the common use of over-the-counter NSAIDS among people who exercise regularly, such findings may have important public health ramifications. However, further research is needed both to confirm the results of this first preliminary study of the timing of NSAID use on skeletal adaptations to exercise training and to determine the extent to which the findings can be generalized to other types and doses of NSAIDs and populations other than premenopausal women. It also will be necessary to determine the mechanisms by which timing of NSAID use relative to exercise influences skeletal adaptations.

This research was supported by Department of Defense Award DAMD-17-01-1-0805 and National Institutes of Health Awards R01 AG018857, M01 RR000051 (General Clinical Research Center) and P30 DK048520 (Clinical Nutrition Research Unit).


All the authors state that they have no conflicts of interest.

1. Alam I,Warden SJ,Robling AG,Turner CH. Mechanotransduction in bone does not require a functional cyclooxygenase-2 (COX-2) geneJ Bone Miner Res.Year: 20052043844615746988
2. Bakker AD,Klein-Nulend J,Burger EH. Mechanotransduction in bone cells proceeds via activation of COX-2, but not COX-1Biochem Biophys Res Commun.Year: 200330567768312763047
3. Bauer DC,Orwoll ES,Fox KM,et al. Aspirin and NSAID use in older women: effect on bone mineral density and fracture risk. Study of Osteoporotic Fractures Research GroupJ Bone Miner Res.Year: 19961129358770694
4. Carbone LD,Tylavsky FA,Cauley JA,et al. Association between bone mineral density and the use of nonsteroidal anti-inflammatory drugs and aspirimpact of cyclooxygenase selectivityJ Bone Miner Res.Year: 2003181795180214584890
5. Cheng MZ,Zaman G,Rawlinson SC,Pitsillides AA,Suswillo RF,Lanyon LE. Enhancement by sex hormones of the osteoregulatory effects of mechanical loading and prostaglandins in explants of rat ulnaeJ Bone Miner Res.Year: 199712142414309286758
6. Chow JW. Role of nitric oxide and prostaglandins in the bone formation response to mechanical loadingExerc Sport Sci Rev.Year: 20002818518811064853
7. Chow JW,Chambers TJ. Indomethacin has distinct early and late actions on bone formation induced by mechanical stimulationAm J Physiol.Year: 1994267E287E2928074209
8. Chow JW,Fox SW,Lean JM,Chambers TJ. Role of nitric oxide and prostaglandins in mechanically induced bone formationJ Bone Miner Res.Year: 199813103910449626636
9. Forwood MR. Inducible cyclo-oxygenase (COX-2) mediates the induction of bone formation by mechanical loading in vivoJ Bone Miner Res.Year: 1996111681693
10. Gregory LS,Kelly WL,Reid RC,Fairlie DP,Forwood MR. Inhibitors of cyclo-oxygenase-2 and secretory phospholipase A2 preserve bone architecture following ovariectomy in adult ratsBone.Year: 20063913414216473054
11. Hinz B,Cheremina O,Brune K. Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in manThe FASEB Journal.Year: 20082238339017884974
12. Jiang Y,Zhao J,Genant HK,Dequeker J,Geusens P. Bone mineral density and biomechanical properties of spine and femur of ovariectomized rats treated with naproxenBone.Year: 1998225095149600785
13. Kasukawa Y,Miyakoshi N,Srivastava AK,et al. The selective cyclooxygenase-2 inhibitor celecoxib reduces bone resorption, but not bone formation, in ovariectomized mice in vivoTohoku J Exp Med.Year: 200721127528317347553
14. Kimmel DB,Coble T,Lane N. Long-term effect of naproxen on cancellous bone in ovariectomized ratsBone.Year: 1992131671721576013
15. Kis B,Snipes JA,Busija DW. Acetaminophen and the Cyclooxygenase-3 Puzzle: Sorting out Facts, Fictions, and UncertaintiesJ Pharmocol Exp Therapeut.Year: 200531517
16. Kohrt WM,Ehsani AA,Birge SJ Jr.. Effects of exercise involving predominantly either joint-reaction or ground-reaction forces on bone mineral density in older womenJ Bone Miner Res.Year: 199712125312619258756
17. Kohrt WM,Ehsani AA,Birge SJ. HRT preserves increases in bone mineral density and reductions in body fat after a supervised exercise programJ Appl Physiol.Year: 199884150615129572792
18. Lane N,Coble T,Kimmel DB. Effect of naproxen on cancellous bone in ovariectomized ratsJ Bone Miner Res.Year: 19905102910352080715
19. Lane NE,Bauer DC,Nevitt MC,Pressman AR,Cummings SR. Aspirin and nonsteroidal antiinflammatory drug use in elderly women: effects on a marker of bone resorption. The Study of Osteoporotic Fractures Research GroupJ Rheumatol.Year: 199724113211369195522
20. Li J,Burr DB,Turner CH. Suppression of prostaglandin synthesis with NS-398 has different effects on endocortical and periosteal bone formation induced by mechanical loadingCalcif Tissue Int.Year: 20027032032912004337
21. Li M,Thompson DD,Paralkar VM. Prostaglandin E(2) receptors in bone formationInt Orthop.Year: 20073176777217593365
22. Moldoveanu AI,Shephard RJ,Shek PN. The cytokine response to physical activity and trainingSports Med.Year: 20013111514411227979
23. Morton DJ,Barrett-Connor E,Schneider DL. Nonsteroidal anti-inflammatory drugs and bone mineral density in older women: the Rancho Bernardo studyJ Bone Miner Res.Year: 199813192419319844111
24. Mundy GR. Osteoporosis and inflammationNutr Rev.Year: 200765S147S15118240539
25. Nieman DC,Davis JM,Brown VA,et al. Influence of carbohydrate ingestion on immune changes after 2 h of intensive resistance trainingJ Appl Physiol.Year: 2004961292129814672962
26. Paulsen G,Benestad HB,Strom-Gundersen I,Morkrid L,Lappegard KT,Raastad T. Delayed leukocytosis and cytokine response to high-force eccentric exerciseMed Sci Sports Exerc.Year: 2005371877188316286856
27. Pead MJ,Lanyon LE. Indomethacin modulation of load-related stimulation of new bone formation in vivoCalcif Tissue Int.Year: 19894534402504461
28. Raisz LG. Potential impact of selective cyclooxygenase-2 inhibitors on bone metabolism in health and diseaseAm J Med.Year: 2001110Suppl 3A43S45S11173049
29. Richards JB,Joseph L,Schwartzman K,Kreiger N,Tenenhouse A,Goltzman D. The effect of cyclooxygenase-2 inhibitors on bone mineral density: results from the Canadian Multicentre Osteoporosis StudyOsteoporos Int.Year: 2006171410141916791706
30. Saino H,Matsuyama T,Takada J,Kaku T,Ishii S. Long-term treatment of indomethacin reduces vertebral bone mass and strength in ovariectomized ratsJ Bone Miner Res.Year: 199712184418509383689
31. Shen CL,Yeh JK,Wang X. Short-term supplementation of COX-2 inhibitor suppresses bone turnover in gonad-intact middle-aged male ratsJ Bone Miner Metab.Year: 20062446146617072738
32. Sibonga JD,Bell NH,Turner RT. Evidence that ibuprofen antagonizes selective actions of estrogen and tamoxifen on rat boneJ Bone Miner Res.Year: 1998138638709610751
33. Somjen D,Binderman I,Berger E,Harell A. Bone remodelling induced by physical stress is prostaglandin E2 mediatedBiochim Biophys Acta.Year: 1980627911006243497
34. Thorsen K,Kristoffersson AO,Lerner UH,Lorentzon RP. In situ microdialysis in bone tissue. Stimulation of prostaglandin E2 release by weight-bearing mechanical loadingJ Clin Invest.Year: 199698244624498958205
35. van Staa TP,Leufkens HG,Cooper C. Use of nonsteroidal anti-inflammatory drugs and risk of fracturesBone.Year: 20002756356811033453
36. Zaman G,Suswillo RF,Cheng MZ,Tavares IA,Lanyon LE. Early responses to dynamic strain change and prostaglandins in bone-derived cells in cultureJ Bone Miner Res.Year: 1997127697779144343


[Figure ID: fig01]
Fig. 1 

Changes in fat mass and fat-free mass in response to exercise training. Values are mean ± SE.

[Figure ID: fig02]
Fig. 2 

Relative changes (%) in bone mineral density (BMD) adjusted for baseline BMD in response to exercise training in participants who were compliant with the intervention (top panel) and in all participants who finished the intervention (bottom panel). Values are mean ± SE. *Different from the other groups, p ≤ .01. Different from the other groups, p ≤ .05.

[TableWrap ID: tbl1] Table 1 

Baseline Characteristics of Compliant Participants

N (%) or mean ± SD and p values for comparisons by group

Variable Category IBUP/PLAC PLAC/PLAC PLAC/IBUP p Value
Hormonal contraceptives No 9 (52.9) 14 (60.9) 7 (50.0) 0.784
Yes 8 (47.1) 9 (39.1) 7 (50.0)
Ethnicity White 14 (82.4) 20 (87.0) 14 (100.0) 0.404
Hispanic 2 (11.8) 2 (8.7) 0 (0.0)
Other 1 (5.9) 1 (4.3) 0 (0.0)
Age, years 30.8 ± 6.2 33.2 ± 5.3 32.1 ± 5.0 0.418
BMI, kg/m2 24.0 ± 4.5 23.6 ± 2.8 23.6 ± 3.0 0.935
Height, cm 165.0 ± 8.5 167.2 ± 7.8 165.2 ± 5.7 0.580
Weight, kg 66.5 ± 9.3 67.0 ± 9.8 64.9 ± 9.4 0.795
Fat mass, kg 21.5 ± 5.2 22.5 ± 6.7 21.0 ± 7.3 0.775
Fat-free mass, kg 45.0 ± 5.1 44.5 ± 5.1 43.8 ± 5.2 0.821
BMD, g/cm2
 Total hip 1.005 ± 0.112 0.982 ± 0.128 0.978 ± 0.116 0.782
 Femoral neck 0.896 ± 0.127 0.886 ± 0.114 0.915 ± 0.125 0.793
 Trochanter 0.755 ± 0.105 0.760 ± 0.098 0.754 ± 0.127 0.980
 Shaft 1.184 ± 0.118 1.150 ± 0.166 1.128 ± 0.130 0.552
 Lumbar spine 1.092 ± 0.124 1.130 ± 0.122 1.061 ± 0.152 0.293

IBUP = ibuprofen; PLAC = placebo; BMI = body mass index; BMD = bone mineral density.

[TableWrap ID: tbl2] Table 2 

Baseline Characteristics by Use of Hormonal Contraceptive Therapy

Mean ± SD or n (%) and p values for comparisons by OC uUse

Variable Category Yes No p Value
Ethnicity White 20 (83.3) 28 (93.3) 0.653
Hispanic 3 (12.5) 1 (3.3)
Other 1 (4.2) 1 (3.3)
Age, years 31.0 ± 4.6 33.1 ± 6.0 0.173
BMI, kg/m2 22.9 ± 2.2 24.3 ± 4.1 0.119
Height, cm 166.7 ± 6.8 165.4 ± 8.1 0.515
Weight, kg 64.5 ± 8.2 67.8 ± 10.2 0.204
Fat mass, kg 20.2 ± 5.2 23.1 ± 6.9 0.095
Fat-free mass, kg 44.3 ± 4.7 44.6 ± 5.4 0.786
BMD, g/cm2
 Total hip 0.986 ± 0.128 0.990 ± 0.113 0.890
 Femoral neck 0.901 ± 0.131 0.894 ± 0.112 0.832
 Trochanter 0.751 ± 0.112 0.762 ± 0.103 0.714
 Shaft 1.154 ± 0.143 1.156 ± 0.144 0.947
 Lumbar spine 1.098 ± 0.140 1.102 ± 0.126 0.925

[TableWrap ID: tbl3] Table 3 

Average (Mean ± SD) Volume of Exercise Performed in Months 2 and 8 of the 9-Month Intervention

Weeks 5–8 Weeks 29–32

Repetitions Weight, lb Repetitions Weight, lb
Resistance exercises
 Leg extensiona 39 ± 10 44 ± 16 26 ± 12 52 ± 26
 Leg flexiona 41 ± 9 44 ± 14 26 ± 13 52 ± 26
 Leg pressa 35 ± 19 86 ± 52 28 ± 15 128 ± 61
 Lat pulldown 42 ± 9 107 ± 33 27 ± 14 131 ± 62
 Bench press 41 ± 8 63 ± 20 26 ± 13 79 ± 36
 Overhead press 40 ± 8 40 ± 13 26 ± 12 49 ± 21
 Biceps curla 40 ± 8 22 ± 6 25 ± 13 24 ± 11
 Triceps extensiona 41 ± 8 15 ± 5 27 ± 13 22 ± 12
 Seated row 32 ± 20 57 ± 38 26 ± 14 88 ± 42
Box jumps, number/week 110 ± 33 121 ± 60
 Height, in 10.0 ± 0.4 15.7 ± 1.0
Stairs, flights/week 4.3 ± 3.4 8.6 ± 4.0
Weight-bearing endurance exercises
 Duration, minutes/week 97.3 ± 40.0 103.0 ± 73.0
 Heart rate, beats/min 154.6 ± 12.2 157.0 ± 11.3

aExercises performed unilaterally.

Article Categories:
  • Original Article

Keywords: exercise training, bone mineral density, nonsteroidal anti-inflammatory drugs, cyclooxygenase, prostaglandins.

Previous Document:  Increased prevalence of bisphosphonate-related osteonecrosis of the jaw with vitamin D deficiency in...
Next Document:  Dramatic increase in cortical thickness induced by femoral marrow ablation followed by a 3-month tre...